Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities: 2019-2021

Historic Total Non-Current Liabilities for Keros Therapeutics (KROS) over the last 2 years, with Sep 2021 value amounting to $11.5 million.

  • Keros Therapeutics' Total Non-Current Liabilities rose 54.74% to $11.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $11.5 million, marking a year-over-year increase of 54.74%. This contributed to the annual value of $7.7 million for FY2020, which is 25.93% down from last year.
  • Per Keros Therapeutics' latest filing, its Total Non-Current Liabilities stood at $11.5 million for Q3 2021, which was up 47.54% from $7.8 million recorded in Q2 2021.
  • In the past 5 years, Keros Therapeutics' Total Non-Current Liabilities registered a high of $11.5 million during Q3 2021, and its lowest value of $7.4 million during Q3 2020.
  • In the last 3 years, Keros Therapeutics' Total Non-Current Liabilities had a median value of $9.1 million in 2020 and averaged $9.1 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first decreased by 25.93% in 2020, then surged by 54.74% in 2021.
  • Keros Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $10.3 million in 2019, then declined by 25.93% to $7.7 million in 2020, then skyrocketed by 54.74% to $11.5 million in 2021.
  • Its Total Non-Current Liabilities stands at $11.5 million for Q3 2021, versus $7.8 million for Q2 2021 and $9.3 million for Q1 2021.